Quincy Bioscience
TINA.org investigated Quincy Bioscience’s marketing of its brain supplement Prevagen, and was involved as amicus curiae in two separate lawsuits filed against the company. To read more about those efforts, click here.
Brands
Featured
Prevagen Memory Study Falls Short
TINA.org, AARP and others file legal brief urging court to reverse dismissal of Prevagen case.
The Latest
Will Prevagen’s Deceptive Advertising Ever End?
Eight years after TINA.org alerted regulators, supplement ads continue to convey deceptive and misleading memory improvement claims.
Prevagen: The Dismal Facts & Figures that Led to TINA.org’s Objection
Pending class-action settlement leaves consumers behind.
FTC Brain Claims Cases Since 1995
Since 1995, the FTC has brought nearly 70 actions over deceptive brain claims.
Five Reasons the BBB Shouldn’t Be Your Only Stop
Researching a company shouldn’t be one-stop shopping.
How Amazon Promotes, Profits from Deceptively Marketed Brain Supplements
The largest retailer in the world isn’t just turning a blind eye to the deceptive marketing of these products.
5 Ad Trends to Be Wary of in 2020
CGI influencers are here.
Thinking about Taking a Supplement for Brain Health? Not So Fast
Brain experts say save your money.
Comment at FDA Public Meeting on Dietary Supplements
Comment made by TINA.org executive director, Bonnie Patten at the FDA’s public meeting on Responsible Innovation in Dietary Supplements held on May 16, 2019. Thank you for the opportunity to…
Prevagen Is Going to the Dogs
Second Circuit rules FTC/NY case against Prevagen can proceed.
2nd Circ. Saves FTC Oversight Of Red-Hot Memory Aid Sector
Jeff Overly, Law360
Class-Action Tracker
Prevagen Dietary Supplements
December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…
Quincy Bioscience’s Prevagen
December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…
Prevagen Supplement
December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…
Prevagen Products
December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…
Quincy Bioscience’s Prevagen Supplement
December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…
Prevagen Dietary Supplement
December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…
Prevagen Supplements
A false advertising class-action lawsuit against Quincy Bioscience was dismissed in June 2016. The complaint, which was originally filed in state court in March 2015 and transferred to federal court…